Ask a Question

Ask your question and our customer service team will answer it as soon as they can. Questions that do not contain personal information may be posted to our help center to be of service to others

* Required field

Your Email Address *

Please enter a valid email address.

Choose a Topic *

Tell us your question and any additional information *

Please enter all required fields.

A Clinical Research Study is Now Recruiting Adults with B Cell NHL

See If You Prequalify

Those who enroll in the study will be asked to take part in another separate follow-up study so researchers can understand the long-term impact of this treatment for up to 13 years.

About the TRANSCEND FL Study

The purpose of the TRANSCEND FL Study

The TRANSCEND FL clinical research study seeks to determine if the experimental therapy called JCAR017 is effective and safe to treat follicular lymphoma or marginal zone lymphoma, and you may be able to take part.

Clinical research studies aim to evaluate how medications work in the volunteers who take them. Researchers use clinical research studies to:

• Answer specific health questions
• Learn about the effects and safety of new study medications
• Help find new ways of using approved medications

See If You Prequalify

What does the TRANSCEND FL Study involve?

Researchers are trying to find new ways to treat follicular lymphoma and marginal zone lymphoma, which are two types of indolent B cell non-Hodgkin lymphoma (NHL). Clinical research studies are an important part of this research, and volunteers are vital to these trials. Without clinical trials and volunteer participants, clinical research would not be possible.

The TRANSCEND FL clinical research study is investigating JCAR017’s use in cancer treatment. We are studying CAR T cell therapy to see whether it works with the body’s own immune system to help fight cancer. The TRANSCEND FL Study is looking for adults ages 18 and older who have been diagnosed with follicular lymphoma or marginal zone lymphoma, either of which has returned (relapsed) or has not responded to current or previous treatments (refractory). Approximately 150 participants will be selected.

How long is the study?

26

months (approximately)
18

research site visits

Those who enroll in the study will be asked to take part in another separate follow-up study so researchers can understand the long-term impact of this treatment for up to 13 years.

Question:

Who is eligible for the study?

Answer:

Eligible participants must: • Be male or female 18 years of age or older • Have been diagnosed with follicular lymphoma or marginal zone lymphoma • Have had their disease return (relapse) or not respond to current or previous treatments (refractory) • Not have received previous CAR T cell therapy or other genetically modified T cell therapy

More FAQs

Question:

What is a clinical research study?

Answer:

A clinical research study, also called a clinical trial, looks at an investigational medication or medical device to see if it is safe, how it works in the body, and if it works to treat a specific disease. Clinical research studies are conducted by doctors who are responsible for the study participants’ study-related care. In most countries, the regulatory health authority, such as the Food and Drug Administration (FDA) in the United States, requires that several phases of clinical research be performed to better understand the safety and efficacy of new investigational medications and certain medical devices. Clinical research studies must be approved by an institutional review board (IRB) or ethics committee (EC). An IRB/EC is a group that is responsible for helping to protect the rights and welfare of study participants. In addition, every study participant is monitored with study-related medical tests and exams before, during, and sometimes even after the study.

More FAQs

Question:

Can I leave the study if I change my mind?

Answer:

Participation in any clinical research study is completely voluntary, and participants may choose to leave the study at any time for any reason. If you would like to leave the study, you should discuss this with your study doctor, who will give you information about how to do this safely.

More FAQs

Question:

What should I expect?

Answer:

Before you can take part in the TRANSCEND FL Study, you will first need to attend the screening visit for initial tests and assessments to see if you are eligible to participate. After all necessary tests and assessments have been completed, and if you are eligible to participate, you may enter the study and receive the experimental therapy.

More FAQs

Available Clinical Trials

Below you will find a clinical trial that is sponsored by Bristol Myers Squibb (BMS). Click the “View Trial Detail” link below to get more information about the trial. From the top of the trial page, click the purple “Pre-Screen Now” button to answer a few questions and find out if you match to the clinical trial. If you are not a match and you are a match for a trial sponsored by another company, you will be shown those trials to consider.

JCAR017-FOL-001

Recruiting

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Juno Therapeutics and Celgene are wholly owned subsidiaries of Bristol-Myers Squibb Company

View Trial Detail

NDS-DLBCL-003

Recruiting

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Detail

About the study periods

This study will have four cohorts, or patient groups. Eligible participants will be assigned to one of these patient groups depending on the following criteria: if they have follicular lymphoma or marginal zone lymphoma, the number and type of treatments they have received in the past, and how long it took for their lymphoma to return after the last treatment. The study consists of three periods, which are pretreatment, treatment, and posttreatment.

Pretreatment

The study doctor will perform tests to determine if an individual is eligible to enroll in the study, which can take up to two weeks. Those who are eligible and consent to participate will then go through a process called leukapheresis (pronounced loo-ka-fer-ee-ses). During this process, some of the participant’s white blood cells are collected from them. The participant’s blood sample is drawn into a machine that collects some of the body’s T cells (a subset of white blood cells that are part of the immune system and can attack things like infections and cancer cells, but also some healthy cells). Those T cells are then sent to a laboratory-based manufacturing facility, where they are modified to make the participant’s own JCAR017 therapy before being infused into their body.

Study Treatment

Once a participant’s JCAR017 T cells are produced, and if their condition allows them to receive the treatment, they will take part in the study treatment period of this study. During this time, they will receive lymphodepleting chemotherapy, followed by infusion of the JCAR017 T cells. Participants will be closely monitored for four weeks after the JCAR017 T cell infusion.

Posttreatment

The study doctor will continue to assess each participant’s condition closely during the posttreatment period and arrange follow-up visits at approximately 2, 3, 6, 9, 12, 18, and 24 months after the JCAR017 T cell infusion.

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -

Call 855-907-3286 or email clinical.trials@bms.com